MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer

Table 3 Univariate and multivariate analyses of the prognostic value of miR-125b-5p, miR-205-5p and miR-424-3p expression levels and clinical parameters in relation to relapse-free survival ^a

	Number of samples	Univariate		Multivariate
	Number of samples	HR (95% CI)	P -value ^b	HR (95% CI)	P -value ^b
miR-125b-5p expression levels	65	6.80 (1.35 to 35.26)	0.009	6.35 (1.21 to 33.27)	0.029
miR-205-5p expression levels	65	1.86 (0.63 to 10.40)	NS (0.17)	ND	ND
miR-424-3p expression levels	65	1.04 (0.52 to 7.58)	NS (0.31)	ND	ND
Age (≤50 yr; >50 yr)	65	0.02 (0.54 to 2.03)	NS (0.90)	ND	ND
Macroscopic tumor size (≤30 mm; >30 mm)	64^c	1.47 (0.08 to 1.89)	NS (0.22)	ND	ND
Lymph node status (≤3; >3)	65	7.68 (1.42 to 33.15)	0.006	6.29 (1.27 to 31.07)	0.024
Histological grade (SBR1 + SBR2; SBR3)	65	0.45 (0.35 to 8.18)	NS (0.50)	ND	ND
Histological grade (SBR1; SBR2)	22	1.41 (0.01 to 3.49)	NS (0.23)	ND	ND
Histological grade (SBR1; SBR3)	47	0.48 (0.06 to 4.00)	NS (0.49)	ND	ND
Histological grade (SBR2; SBR3)	61	1.10 (0.36 to 23.68)	NS (0.29)	ND	ND
ER status (negative; positive)	65	0.17 (0.20 to 2.85)	NS (0.68)	ND	ND
PR status (negative; positive)	65	0.10 (0.21 to 3.04)	NS (0.75)	ND	ND
HER2 status (negative; positive)	65	0.78 (0.48 to 6.84)	NS (0.38)	ND	ND

^a95% CI, 95% confidence interval; ER, Estrogen receptor; HER2, Human epidermal growth factor receptor 2; HR, Hazard ratio; miR, MicroRNA; ND, Not done; NS, Not significant; PR, Progesterone receptor; SBR, Scarff-Bloom-Richardson grade. ^b P < 0.05 was considered significant. ^cInformation available for 64 patients.